Table 2.
Procedural Results and 30-Day Clinical Events
| Ridaforolimus-Eluting Stent (N=958 patients, 1326 Lesions) | Zotarolimus-Eluting Stent (N=961 patients, 1305 Lesions) | P Value | |
|---|---|---|---|
| No. of stents | |||
| Per patient | 1.6±0.9 | 1.6±0.8 | 0.17 |
| Per lesion | 1.2±0.5 | 1.1±0.5 | 0.49 |
| Per target vessel | 1.4±0.7 | 1.3±0.6 | 0.33 |
| Total stent length (mm) | |||
| Per patient | 33±20.9 | 31.8±19.7 | 0.48 |
| Per lesion | 24.3±14 | 23.7±12 | 0.33 |
| Stent diameter (mm) | 3.04±0.44 | 3.02±0.45 | 0.42 |
| >1 stent implanted | 16.7 (221/1326) | 14.9 (194/1305) | 0.21 |
| Minimal luminal diameter (mm) | |||
| Preprocedure in-lesion | 0.78±0.40 | 0.81±0.40 | 0.07 |
| Postprocedure in-stent | 2.50±0.45 | 2.54±0.47 | 0.002 |
| Postprocedure in-segment | 2.29±0.47 | 2.31±0.49 | 0.13 |
| Diameter stenosis (%) | |||
| Preprocedure in-lesion | 71.5±13.4 | 70.7±12.8 | 0.15 |
| Postprocedure in-stent | 11.7±7.7 | 10.9±8.3 | 0.002 |
| Postprocedure in-segment | 16.4±9.2 | 16.3±9.6 | 0.40 |
| Acute gain (mm) | |||
| In stent | 1.7±0.5 | 1.7±0.5 | 0.19 |
| In segment | 1.5±0.5 | 1.5±0.5 | 0.96 |
| Index PCI procedure characteristics (mm) | |||
| Balloon predilation | 75.4 (1000/1326) | 72.0 (940/1305) | 0.05 |
| Postdilation | 60.3 (800/1326) | 56.7 (740/1305) | 0.06 |
| FFR performed | 4.9 (65/1326) | 4.8 (62/1305) | 0.86 |
| Device success* | 98.0 (1243/1268) | 99.4 (1261/1268) | 0.001 |
| Lesion success† | 99.9 (1257/1258) | 99.8 (1262/1264) | 0.99 |
| Procedure success‡ | 97.6 (929/952) | 97.3 (928/954) | 0.67 |
| 30-day outcomes (mm) | |||
| Death | 0.5 (5/955) | 0.2 (2/958) | 0.29 |
| Myocardial infarction, any | 2.8 (27/953) | 3.2 (31/956) | 0.60 |
| Q-wave myocardial infarction | 0.5 (5/953) | 0.4 (4/956) | 0.75 |
| Non-Q-wave myocardial infarction | 2.4 (23/952) | 2.8 (27/956) | 0.58 |
| Stent thrombosis | 0.4 (4/952) | 0.4 (4/957) | 0.99 |
| TLF§ | 2.6 (25/954) | 3.2 (31/957) | 0.42 |
| TVF¶ | 2.9 (28/955) | 3.4 (33/958) | 0.52 |
| MACEǁ | 3.0 (29/954) | 3.6 (34/957) | 0.53 |
FFR indicates fractional flow reserve; MACE, major adverse cardiac events; PCI, percutaneous coronary intervention; TLF, target lesion failure; TVF, target vessel failure; QCA, quantitative coronary angiography. Values are % (n/N) or mean±SD.
Device success: final in-stent residual QCA diameter stenosis of <50% using the assigned device only and without a device malfunction.
Lesion success: final in-stent residual QCA diameter stenosis of <50% using any percutaneous method.
Procedure success: final in-stent QCA diameter stenosis of <50% using the assigned device or with any adjunctive devices, without the occurrence of cardiac death, Q wave or non-Q wave MI, or repeat revascularization of the target lesion during the hospital stay.
Target lesion failure defined as the composite rate of cardiac death, target vessel myocardial infarction, or clinically driven target lesion revascularization.
Target vessel failure defined as the composite rate of all-cause death, target vessel-related myocardial infarction, or clinically driven target vessel revascularization.
Major adverse cardiac events defined as the composite rate of cardiac death, any myocardial infarction, or clinically driven target lesion revascularization.